Value through InnovationMay 31 2016

Boehringer Ingelheim Press Releases

See the latest Boehringer Ingelheim press releases. To quickly find all press releases on a specific topic, please use the search.

Press Release Archive

back 1 2 3 4 5 6 7 8 9 10

U.S. FDA Approves Once-daily Jentadueto® XR (linagliptin and metformin hydrochloride extended-release) Tablets for Adults with Type 2 Diabetes


Boehringer Ingelheim Launches “Conoce a Don Francisco” Sweepstakes


New Presentations at ATS 2016 Reinforce OFEV® (nintedanib) Efficacy, Safety and Tolerability Across Range of Patients with IPF


Jardiance® (empagliflozin) to be studied for the treatment of people with chronic heart failure


Boehringer Ingelheim has a successful 2015 financial year


FDA approves Gilotrif® (afatinib) as new oral treatment option for patients with squamous cell carcinoma of the lung


Head-to-head study demonstrating Gilotrif® (afatinib) significantly improved clinical outcomes compared to Iressa® (gefitinib) in EGFR mutation-positive advanced non-small cell lung cancer published in The Lancet Oncology


Lancet Publication: New Analysis Demonstrates Only Small Minority of Severe/Very Severe COPD Patients May Benefit from Adding ICS to SPIRIVA® HANDIHALER® (tiotropium bromide inhalation powder) + LABA Therapy


New Survey: People Living with Asthma Believe it is Controlled, But Persistent Symptoms and Limits to Everyday Activities Tell a Different Story


Interim Phase III Data Show Praxbind® (idarucizumab) Reverses Dabigatran (Pradaxa®) in Emergency Situations

back 1 2 3 4 5 6 7 8 9 10